SerpinopathiesProject reference: 300272
Funded under :
Determination of the structure of the pathological neuroserpin polymer and development of an intrabody strategy to prevent disease-associated inclusions in cell and animal models of disease
Total cost:EUR 200 371,8
EU contribution:EUR 200 371,8
Coordinated in:United Kingdom
Topic(s):FP7-PEOPLE-2011-IEF - Marie-Curie Action: "Intra-European fellowships for career development"
Call for proposal:FP7-PEOPLE-2011-IEFSee other projects for this call
Funding scheme:MC-IEF - Intra-European Fellowships (IEF)
An increasing number of human disorders are recognised to result from the aggregation and tissue deposition of misfolded proteins. This group of diseases has been termed the conformational disorders and comprises such diseases as Alzheimer’s, Huntington’s and Parkinson’s disease as well as the amyloidoses and the serpinopathies. The serpinopathies are characterized by the polymerisation and tissue deposition of mutants of members of the serine protease inhibitor or serpin superfamily of proteins. One of the most striking serpinopathies is familial encephalopathy with neuroserpin inclusion bodies (FENIB) that is caused by one of six naturally occurring point mutations in the neuroserpin gene. Mutant neuroserpin forms ordered polymers that accumulate within the endoplasmic reticulum of neurons, resulting in progressive dementia, with the age of onset of disease being inversely proportional to the rate of polymer formation in vitro and the number of intra-cerebral inclusions. This study will use an anti-polymer monoclonal antibody to (i) define the structure of the pathological neuroserpin polymer and its time-dependent appearance in the ER and (ii) as the basis for an intrabody strategy to prevent the inclusions associated with disease. First, regions of neuroserpin that are exposed upon transition from monomer to polymer will be analyzed by epitope mapping using differential chemical modification and crystallization aided by an antibody-engineered construct. Second, the ability of this anti-polymer monoclonal antibody to prevent pathogenic polymer formation and to impact their intracellular localization pattern will be assessed by co-expression with different neuroserpin mutants in cell and fly models of disease. The protective efficacy in vivo will be addressed by analyzing the locomotor phenotype in flies. If successful, an intracellular antibody based approach may be used to treat the serpinopathies and other ‘gain of function’ conformational diseases.
EU contribution: EUR 200 371,8
WC1E 6BT LONDON
Tel.: +44 2031083033
CB2 1TN CAMBRIDGE
Tel.: +44 1223 333543
Fax: +44 1223 332988